Key Points The addition of rituximab to corticosteroid and CsA is safe and effective for first-line treatment of cGVHD. Resistance of PD-L1hi B cells to anti-CD20 depletion may lead to the suppression of activated Tfh cells and cGVHD control.
No takes yet. Share an insight, caveat, or question.
Malard et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: